Kristin, you, morning. Thank good and
In X% international As second as segments. a animal reported with our Kristin basis growth we strong an revenue companion and basis. well balanced a had both as on mentioned, U.S and growing quarter, and of generated we the on operational billion, portfolios, quarter X% our across $X.X livestock second
XX% basis. products, X% operational products, from Adjusted Of million X% other price and revenue portfolio. net our income XX% from X% X% of Volume on on for operational an growth, growth were X% the of our X% from new osteoarthritis from key monoclonal from reported in-line and antibodies basis including is pain $XXX dermatology consisted volume. a and is
livestock Companion in operationally growth X% primary of on the growing an this driver animal XX% quarter, basis are quarter. the products operational with growing
ever the contributor quarter, portfolio $XXX an key operational to dermatology in our quarter on basis. animal, growth in representing growth companion million was largest and For posting revenue, our largest the XX%
in and U.S. growth growth well by operational as by driven in as international strong We the saw the conversion Apoquel to growth markets. international certain and double-digit Apoquel driven Cytopoint both in Chewable
launch pain dogs cats, quarter of with the of osteoarthritis several in as Solensia million Librela in both and impact for well antibodies $XX in the monoclonal globally in new markets. Librela and products for as posted strong Our the revenue international demand
growth the the Our and contributed grew which parasiticide companion with Trio in also also to of driven revenue million of $XXX and contributed X% operationally. Simparica XX% our quarter, parasiticides $XXX growth to revenue million franchise, operationally. animal in had growth Revolution by
high and field cattle We model across quarter. of saw in our in prior growth operational X% operationally. Sales animal that growth the $XX disruptions implementation quarter driven the placements Our force million of segments saw We livestock from recorded products poultry, driven basis and global in XX% companion diagnostics revenue the our year. by in by the growing instrument international impacted double-digit the on an both new and grew portfolio our in U.S. QX, U.S. fish.
growing the companion Now in billion by X%. growing X% to animal revenue quarter, with moving on quarter. growing products segment U.S. sales for X% livestock revenue growth $X.X the was and
that quarter reflects the headwind performance of As to growth distributor a Kristen mentioned, levels QX. in animal our were the stabilization companion inventory in the our
to U.S. visit trends and vet line continue up [Indiscernible] were visits average growth the with X%. revenue and flat were per are in quarter. both the stabilization revenue These expectations post-COVID. in reflect
performance. product U.S. to Turning
were showing and growing with million in periodic preference for the Cytopoint from Our sales visits pet $XXX sales vets key and to for quarter, growth higher drive continue injectables. dermatology patient benefited product owners quarter. a the XX%
part competitor into higher order as grew well animal quarter, virus vaccine our strategic and a corporate small accounts. U.S. driven as by XX% vaccines canine due certain higher of sales revenue to sales the in in influenza Our back
$XXX from our difficult year current distributor million by challenges as aggressive across comparison period Apoquel given quarter. during Chewable the quarter, in growing in competitive partially promotion sales shipments timing was a of as channels, driven posted Growth supply of well inpatient offset demand X%. all the by last the
growth supply in and we cadence Our expect XXXX, year of recovery the for impacted the rate will in across half. timing by be the second growth Trio improvement
May. early in We received Librela we QX starting November launch. forward program As for in U.S. our expected, experience approval look expected with the an in to late FDA
cattle quarter. We in growth quarter, livestock reduction our anticipated a sales Now limited our favorable in quarter year Jackson, saw primarily from the from comparative portfolio significant last turning price to in U.S. midyear the livestock. resulting X% business in where we saw when an growth
growth cattle claim. from reimplementation label U.S. our benefited from came Additional Synovex, which
market. also portfolio and layer portfolio XX% to growth poultry an vaccine of U.S. increased our Our contributed on focus on based egg
rotations MFA favorable from at certain benefited also large We producers.
our Moving X% operationally International quarter, $X and while revenue to on grew the revenue livestock on the grew operationally growing was International operationally. a companion reported basis animal quarter. X% XX% billion, XX% segment, where in revenue in
Increased resulted pain our sales of companion animal dermatology key from our small animal monoclonal of parasiticides, and antibodies our for products. osteoarthritis products growth
was in revolution driven portfolio driven primarily by lack the by XX% growing which Our growth impacted parasiticide supply second a XXXX. operationally year, $XX revenue, with last in international quarter of of million franchise particularly China the
Simparica also Latin expansion, continued market in to Our and growth franchise Asia. Europe America, contributed with especially share
We continue to adoption Solensia. of and strong see Librela
various Canada, in driven direct-to-consumer advertising in the Europe, markets major million by efforts operational in quarter strong growth our generated recent including growth and revenue supported international Japan. and $XX Brazil in with launches Australia, Librela in markets, XX% by
demand million supported direct-to-consumer $XX second delivered marketing by higher sales and quarter Solensia internationally, driven efforts. by of
dermatology XX% international operationally. grew Our portfolio key
Chewable by from Cytopoint well We with from driven markets, our new continue as across operational conversion patients. of to growth Apoquel growth to and higher as and compliance see most major double-digit
Our impacted growth QX comparative also which benefited buy from Japan, quarter ups of year. in last a pre-priced by weak in was
on livestock in portfolio, X% an operational basis Moving on the quarter. our international to grew which
poultry well America. poultry driven in growth portfolio account East rotations Latin Our and by penetration markets, Middle performed core and with including MFA key the Europe,
result portfolio sales markets Norway continues of of and vaccines Chile. as across a to perform in Our fish well increased salmon
from gains issues. in and saw of strong supply and portfolio Turkey, Lastly, the recovery Brazil our cattle price Argentina growth
compared the and manufacturing product to costs on prior moving basis the This exchange, was the favorable quarter. higher reported quarter. the by the price P&L partially basis from margin to on of XX.X% foreign Now increases improved resulting in offset Adjusted mix. rest of for favorable year, XXX gross points a
operationally and the lower Adjusted with of XX% in driven a operating expected quarter not of the increases. project new to the growth X% R&D full growing in R&D grown year. by investments adjusted timing compensation for costs and The reflective expenses timing Year-to-date, has expenses X% in headcount-related SG&A is operationally. of of hires operationally this XXXX R&D both increased R&D spend and spend annual due primarily salary reduction expenses impact in our the
for an tax The net year's income. expenses XX.X%, quarter basis earnings, adjusted favorable in higher tax partially intangible in of was discrete by offset jurisdictional positions XX benefit mainly the to tax the by prior to less quarter, driven foreign-derived and changes the rate effective increase related points, higher related of U.S. a mix to
Zoetis And net quarter operationally finally, and track expectations year. to In of quarter, were operationally shares. on our quarter. continue grew expenditures in we with the repurchased adjusted and the the XX% grew in EPS adjusted be income the diluted $XXX second million XX% million Capital $XXX for
foreign reflects revenue revenue operational to the of to moving exchange unfavorable foreign Please our maintaining full while guidance range growth. we late due are year XXXX. as slightly with beginning lowering exchange on rates guidance that on full for our guidance the for Now July, revenue year note
expect $X.XX X% We range billion, to $X.XX between representing and revenue a operational billion of growth. X%
our as With which now in including growth overall of immaterial the are broader projected rate. uncertainty be the expected impact well the December November conditions revenue year to in are in by guidance, as certain macroeconomic largely on operational we Their Librela is sales our offset markets. our full China U.S., approval for potential and to in
has expected operational as growth. the Operationally, X% with played half first largely out we revenue
half, which especially has the stronger on companion in X% second We anticipate We grown business. operational an livestock, expect year basis. animal year-to-date in In half growth unfavorable comparisons U.S. the our in overall, of products the second resumption the several XXXX. in the driven half Jackson the of decreases in after by first in U.S. year, last supply timing price and of the of outages of
previous income billion, guidance billion of exchange were adjusted of in operational to sales unfavorability to while revenue. guidance expect favorability previous by range cost $X.XX in by be foreign our the which X% to expenses, and above of We our net slightly driven growth of $X.XX offset maintaining partially X%, in
increases deal. increasing of impact a a due one-time foreign to $X.XX the exchange diluted EPS in impacted a business foreign range the to to EPS range by gain And Reported of to are exchange, which be finally, from of diluted to is adjusted $X.XX, $X.XX and development $X.XX. we
and growth growing to as Q&A, before saw companion we well in in quarter, U.S. animal price the and both as internationally, summarize to from second go strong livestock based well with Just we in volume. contributions and the
half. as expect We stronger growth we move into the second
remain year ability our full in to our We on confident commitments. operational guidance deliver
in We revenue. improving adjusted market to to continue net industry overall proposition revenue on grow faster our delivering than than and see value grow to and the to fundamentals the remain faster committed income
for hand I'll your things the Now the to Operator? to line questions. operator over open
